Compare Paychex, Inc. (PAYX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Paychex, Inc. trades at $114.91 (market cap $40.85B), while State Street SPDR S&P Biotech ETF trades at $159.61. The key difference: Paychex, Inc. pays a 4.15% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Paychex, Inc. nearer its low. Which is the better fit depends on your goals.
| PAYX | XBI | |
|---|---|---|
Market Cap | $40.85B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $135.46 | $169.55 |
52-Week Low | $85.57 | $93.43 |
Enterprise Value | $44.33B | — |
Dividend Yield | 4.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $116.93, down 3.93% in the last session. The stock shows strong profitability with a net income margin of 27.03% and ROE of 44.77%. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.32 surpassing the $1.31 estimate. Technical indicators are mixed, with a bearish moving average signal but RSI suggesting potential oversold conditions. The company continues to expand its AI-driven WISE platform, enhancing service efficiency for small businesses.
The outlook for PAYX is cautiously optimistic, supported by robust cash flow and strategic AI integration. However, risks include elevated valuation multiples and competitive pressures in the HR solutions space. Analyst consensus is a 'Hold' with a $120 price target, indicating limited near-term upside from current levels amid balanced growth and risk factors.
XBI (SPDR S&P Biotech ETF) trades at $161.97, down 1.12% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF holds over 150 biotech companies, benefiting from strong M&A activity and positive clinical catalysts, though key financial ratios are not applicable for the fund structure. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic given sector tailwinds, but high volatility and concentration in small-cap biotech pose risks. The single analyst covering the ETF maintains a Hold rating, reflecting a neutral stance amid the sector's rally and inherent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
